Adding abemaciclib to imlunestrant more than doubled median progression-free survival in patients with ESR1-mutated metastatic breast cancer: 11.1 months for the combination versus 5.5 months for imlunestrant alone, a hazard ratio of 0.53. That number, drawn from the 159-patient ESR1-mutant cohort of the Phase 3 EMBER-3 trial, is the clinical foundation for the FDA’s full approval of Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after at least one prior line of endocrine therapy. The combination is all-oral and, according to the label, requires no new monitoring beyond what either agent carries individually.
ESR1 mutations develop in roughly half of patients with ER-positive, HER2-negative metastatic breast cancer during or after treatment with aromatase inhibitors, and they drive endocrine resistance by making the estrogen receptor constitutively active. The approval is structured around switching both the endocrine backbone and the CDK4/6 inhibitor at clinical progression rather than earlier, a sequencing decision the trial data actively support. Patients in EMBER-3 had received an aromatase inhibitor with or without a CDK4/6 inhibitor in either the adjuvant or metastatic setting before enrolling. Grade 1-2 adverse events accounted for the majority of toxicity; fewer than 4% of patients discontinued either agent permanently due to adverse reactions. Discontinuation of imlunestrant occurred in 1% of patients and abemaciclib in 3.4%.
This is Lilly’s second FDA approval for imlunestrant in under a year. The monotherapy indication came in September 2025 for the same population and setting; the combination label now gives prescribers an evidence-based option for patients who need both ER and CDK4/6 inhibition addressed simultaneously at progression. The tolerability overlap between the two labels matters practically: physicians already familiar with abemaciclib’s diarrhea and neutropenia profile do not face a learning curve for the combination.
The next data milestone for imlunestrant sits in the adjuvant setting. EMBER-4, with more than 8,000 patients enrolled across 650-plus sites in over 30 countries, is the largest adjuvant oral SERD trial conducted and expects initial results in 2027. Whether imlunestrant can reduce recurrence in early-stage ER-positive, HER2-negative disease will determine how broadly the drug reshapes endocrine therapy across the breast cancer continuum.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
